Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Mounjaro"

19 News Found

Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action
Supply Chain | April 30, 2026

Eli Lilly flags counterfeit Mounjaro products in Gurugram, backs regulatory action

Company confirms seized products were not from its authorised supply chain and urges patients to purchase medicines only through licensed pharmacies


Eli Lilly flags counterfeit Mounjaro seizure in Gurugram
News | April 20, 2026

Eli Lilly flags counterfeit Mounjaro seizure in Gurugram

The company said it is supporting the ongoing investigation and reiterated its commitment to patient safety.


Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity
Clinical Trials | August 02, 2025

Lilly's Mounjaro shows heart health benefits in head-to-head trial with Trulicity

The SURPASS-CVOT study met its primary objective by demonstrating that Mounjaro (tirzepatide) was non-inferior to Trulicity


Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
News | March 24, 2025

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes

Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)


Eli Lilly unveils $4.5 bn Indiana expansion
News | May 07, 2026

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies


Lilly posts explosive Q1 2026 results
News | May 04, 2026

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates


Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds
News | March 14, 2026

Lilly issues urgent warning over potentially dangerous Tirzepatide-B12 compounds

Lilly has long voiced concerns over mass-compounded knockoffs of its tirzepatide medicines, Mounjaro and Zepbound


Lilly expands affordable access to diabetes & obesity medicines under new medicare programme
Supply Chain | March 10, 2026

Lilly expands affordable access to diabetes & obesity medicines under new medicare programme

Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans


Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
Clinical Trials | February 25, 2026

Novo Nordisk unveils weight-loss data from REDEFINE 4 trial

CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide


Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
News | February 05, 2026

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices